ClinicalTrials.gg
Active, not recruitingNCT04439110Updated Nov 18, 2026Results posted

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

A Phase 2 interventional study of Trastuzumab Emtansine in Advanced Lymphoma, Advanced Malignant Solid Neoplasm and Hematopoietic and Lymphoid Cell Neoplasm, sponsored by National Cancer Institute (NCI). Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Aug 2015, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) — 12 open to participants now, 33 under way, none of them phase 3. Hematologic Neoplasms · National Cancer Institute (NCI).

Enrollment
26th of 52
38 · median 38
Started
2015
with 7 others
Phase 2
31 of 60
1 open now
Primary completion
2019-03
later than 0 of 32 live
Registered
29th of 60
by date

Among the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), this one is the 26th largest by enrollment of the 52 interventional ones that give a count, is one of 8 that started in 2015, is one of 31 in phase 2, reaches primary completion later than 0 of the 32 other live ones, and was the 29th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

12 of the 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI) are open now, in 2 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Hematologic Neoplasms by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification. Ado-trastuzumab emtansine is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called DM1. Trastuzumab is a form of "targeted therapy", because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors and delivers DM1 to kill them. Researchers hope to learn if the study drug will shrink this type of cancer or stop its growth.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

SECONDARY OBJECTIVES:

I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced refractory cancers/lymphomas/multiple myeloma.

II. To evaluate time until death or disease progression. III. To identify potential predictive biomarkers beyond the genomic alteration by which treatment is assigned or resistance mechanisms using additional genomic, ribonucleic acid (RNA), protein and imaging-based assessment platforms.

IV. To assess whether radiomic phenotypes obtained from pre-treatment imaging and changes from pre- through post-therapy imaging can predict objective response and progression free survival and to evaluate the association between pre-treatment radiomic phenotypes and targeted gene mutation patterns of tumor biopsy specimens.

OUTLINE:

Patients receive trastuzumab emtansine intravenously (IV) over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months if less than 2 years from study entry, and then every 6 months for year 3 from study entry.

03

Conditions studied

  • Advanced Lymphoma
  • Advanced Malignant Solid Neoplasm
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Refractory Lymphoma
  • Refractory Malignant Solid Neoplasm
  • Refractory Multiple Myeloma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have met applicable eligibility criteria in the Master MATCH Protocol prior to registration to treatment subprotocol
  • Patients' tumor sample must have amplification > 7 based on targeted custom Ampliseq panel on the Ion Torrent Personal Genome Machine (PGM)
  • >= 9.0 g/dL (which may be reached by transfusion)
  • Patients will be allowed if on anticoagulation (except warfarin and other coumarin derivatives) or on aspirin 81 mg by mouth daily. Additional monitoring while on anticoagulation will be based on institutional guidelines and/or physician discretion. However, patients will not be allowed if on long acting anti- agents such as clopidogrel
  • Patients must have an (ECG) within 4 weeks prior to treatment assignment and must have no abnormalities in rhythm, conduction or morphology of resting ECG (e.g. complete left bundle branch block, third degree heart block)
  • Patients must have echocardiography (ECHO) or nuclear study (multigated acquisition scan [] or First Pass) within 4 weeks prior to registration to treatment and must not have a left ventricular ejection fraction (LVEF) \< 50% to be eligible
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 months after completion of study

Exclusion criteria

Exclusion Criteria:

  • Patients with a diagnosis of breast cancer or gastric/gastroesophageal junction (GEJ) cancer will be excluded
  • Patients must not have known to ado-trastuzumab emtansine or compounds of similar chemical or biologic composition
  • Patients with current peripheral neuropathy of grade 3 or greater (National Cancer Institute [NCI]-Common Toxicity Criteria [CTC], version 4.0) will be excluded

    • Neuropathy assessment and grade assignment will be based on history (location, duration, balance and gait, effect on activity of daily living [ADLs]) and physical exam
  • Patient must not have had any of the prior therapies:

    • Food and Drug Administration (FDA) approved:

      • Trastuzumab
      • Pertuzumab
      • Ado-trastuzumab emtansine
    • :

      • Margetuximab
      • PF-05280014 (Pfizer, Trastuzumab Biosimilar)
      • CT-P6 (Celltrion, Trastuzumab Biosimilar)
      • ABP-980 (Amgen, Trastuzumab Biosimilar)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Treatment (trastuzumab emtansine)

    Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

    Biological: Trastuzumab Emtansine

Interventions

  • BiologicalAdo-Trastuzumab EmtansineStudies of Ado-Trastuzumab EmtansineAdo-Trastuzumab Emtansine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO 132365, PRO-132365, PRO132365, RO5304020, T-DM1, TDM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among eligible and treated patients. Objective response rate is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. For each treatment arm, 90% two-sided binomial exact confidence interval will be calculated for ORR.

    Time frame: Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration

Secondary outcomes

  1. 6 Months Progression-free Survival (PFS) Rate

    Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.

    Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration

  2. Progression Free Survival (PFS)

    Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Median PFS will be estimated using the Kaplan-Meier method.

    Time frame: Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration

07

Results

Posted Feb 5, 2021

Participant flow

Subprotocol Q was activated on August 12, 2015. A total of 58 patients were assigned to this arm after screening, all from screening cohort. Of the 58 patients, 38 patients were enrolled to arm Q between November 19, 2015 and March 20, 2017.

Participant flow — Overall Study
MilestoneTreatment (Trastuzumab Emtansine)
Started38
Eligible36
Completed0
Not completed38
Withdrew: Ineligible2
Withdrew: Adverse event4
Withdrew: Death2
Withdrew: Disease proression25
Withdrew: Withdrawal by subject1
Withdrew: Alternative therapy1
Withdrew: Other complicating disease1
Withdrew: Personal reasons1
Withdrew: Still on treatment1

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR is defined as the percentage of patients whose tumors have a complete or partial response to treatment among eligible and treated patients. Objective response rate is defined consistent with Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. For each treatment arm, 90% two-sided binomial exact confidence interval will be calculated for ORR.

Time frame:
Tumor assessments occurred at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsTreatment (Trastuzumab Emtansine)
Objective Response Rate (ORR)2 (1 to 16.5)
Secondary6 Months Progression-free Survival (PFS) Rate

Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. 6 month PFS rate was estimated using the Kaplan-Meier method, which can provide a point estimate for any specific time point.

Time frame:
Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Reported as:
Number · percentage of participants
6 Months Progression-free Survival (PFS) Rate
percentage of participantsTreatment (Trastuzumab Emtansine)
6 Months Progression-free Survival (PFS) Rate23.6 (14.2 to 39.2)
SecondaryProgression Free Survival (PFS)

Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Median PFS will be estimated using the Kaplan-Meier method.

Time frame:
Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration
Reported as:
Median · months
Progression Free Survival (PFS)
monthsTreatment (Trastuzumab Emtansine)
Progression Free Survival (PFS)3.1 (2.1 to 4.4)

Adverse events

Collected over Assessed every 21 days while on treatment and for 30 days after the end of treatment, up to 3 years post registration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Trastuzumab Emtansine)30/38 (78.9%)12/38 (31.6%)29/38 (76.3%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventTreatment (Trastuzumab Emtansine)
AnemiaBlood and lymphatic system disorders3/38
FatigueGeneral disorders2/38
Platelet count decreasedInvestigations2/38
DehydrationMetabolism and nutrition disorders2/38
FeverGeneral disorders1/38
DiarrheaGastrointestinal disorders1/38
Ileal obstructionGastrointestinal disorders1/38
NauseaGastrointestinal disorders1/38
SepsisInfections and infestations1/38
Upper respiratory infectionInfections and infestations1/38
Most frequent other events
Showing 10 of 37
Most frequent other events
EventTreatment (Trastuzumab Emtansine)
FatigueGeneral disorders14/38
Aspartate aminotransferase increasedInvestigations11/38
Platelet count decreasedInvestigations11/38
AnemiaBlood and lymphatic system disorders9/38
NauseaGastrointestinal disorders8/38
VomitingGastrointestinal disorders8/38
Alkaline phosphatase increasedInvestigations6/38
AnorexiaMetabolism and nutrition disorders5/38
Rash acneiformSkin and subcutaneous tissue disorders4/38
Alanine aminotransferase increasedInvestigations4/38

Baseline characteristics

Patients who were eligible and received protocol treatment

Age, Continuous
Age, Continuous(years)Treatment (Trastuzumab Emtansine)
Median64 (39 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Trastuzumab Emtansine)
Female23
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Trastuzumab Emtansine)
Hispanic or Latino2
Not Hispanic or Latino31
Unknown or Not Reported3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Trastuzumab Emtansine)
American Indian or Alaska Native1
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American5
White26
More than one race0
Unknown or Not Reported2
08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Mar 2019, 42 months.

Results were first posted in Feb 2021, 1 year 10 months after primary completion.

Of 114 non-industry phase 2 interventional studies under Hematologic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 95. This study's 42 months is below that.

Counting every sponsor, half of 136 studies reached it within 57 months; a quarter within 40 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2020
First posted
Jun 19, 2020
StartActual
Aug 12, 2015
Primary completionActual
Mar 9, 2019
CompletionEst.
Mar 31, 2027
Results first posted
Feb 5, 2021
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04439110
Responsible party
Sponsor
First posted
Jun 19, 2020
Start date
Aug 12, 2015
Primary completion
Mar 9, 2019
Completion
Mar 31, 2027 (estimated)
Results posted
Feb 5, 2021
Last update
Nov 18, 2026

Study contacts

Komal Jhaveri
principal investigator · ECOG-ACRIN Cancer Research Group

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ado-Trastuzumab Emtansine

Start the discussion